7 rezultatus
BACKGROUND OF THE INVENTION
Obesity is a chronic disease that contributes to numerous, often life-threatening medical conditions, including serious metabolic and cardiovascular diseases. The prevalence of obesity has steadily increased over recent years among various racial and ethnic groups,
TECHNICAL FIELD
The invention relates to compositions of nicotinamide riboside analogs, including esters and carbonates, for use in elevating levels of nicotinamide adenine dinucleotide (NAD.sup.+) in cells and tissues of an organism. The novel compositions include pharmaceuticals compositions and
BACKGROUND
In the early part of the 20.sup.th century, vitamin B.sub.3 was identified as a component missing from the diet of pellagra patients. Supplementation with nicotinic acid, or niacin, ameliorated the symptoms of pellagra, and prevented the onset of this condition in areas where it was
INTRODUCTION
Age-related obesity is a health-related problem for which new treatments and methods of ameliorating, mitigating, or reversing are needed. U.S. Pat. No. 8,268,575 to Imai, S., et al. asserts that "Chemical effectors for mammalian NAD biosynthesis can mediate a variety of anti-aging
INTRODUCTION
Age-related obesity is a health-related problem for which new treatments and methods of ameliorating, mitigating, or reversing are needed. U.S. Pat. No. 8,268,575 to Imai, S., et al. asserts that "Chemical effectors for mammalian NAD biosynthesis can mediate a variety of anti-aging
BACKGROUND OF THE INVENTION
In the Specification of my copending Application Ser. No. 338,257 (U.S. Pat. No. 4,009,265), there is described and claimed a method for the treatment of obesity in man, which comprises the steps of giving the overweight patient a daily diet consisting essentially of,
(a)
CROSS REFERENCE TO FOREIGN APPLICATION
This application claims the benefit of and priority to Japanese Patent Application No. 2017-027373 filed on Feb. 16, 2017 under 35 USC .sctn. 119. This application is hereby incorporated by reference in its entirety.
TECHNICAL FIELD
The present disclosure